Zolmsolan 2.5 mg 6 pcs

МTradename:

Zolmsolan

Compound:

Each mouth-dissolving film contains:

Zolmitriptan 2.5 mg

Auxiliary components:

Polyvinyl alcohol, polyethylene glycol, starch, glycerol, sucrose, menthol oil, simethicone.

Properties:

Zolmitriptan is a selective agonist of 5HT1B / 1D receptors, the stimulation of which leads to vasoconstriction. It has a high affinity for recombinant human 5HT1B / 1D receptors and a moderate affinity for 5HT1A receptors. Zolmitriptan has no affinity and does not show significant pharmacological activity in relation to 5HT2-, 5HT3-, 5HT4-, adrenergic, histamine, muscarinic and dopamine receptors.

Zolmitriptan administration to laboratory animals resulted in vasoconstriction in the carotid artery basin. In addition, the results of studies on laboratory animals indicate that zolmitriptan blocks the central and peripheral activity of the trigeminal nerve by inhibiting the release of the peptide associated with the calcitonin gene, vasoactive intestinal peptide and substance P.

In clinical studies, the effect of zolmitriptan on headache and other migraine symptoms (such as nausea, photophobia, phonophobia) was observed after 1 hour and increased in the period from 2 to 4 hours after taking the drug.

Zolmitriptan is equally effective for migraine with aura, migraine without aura, and migraine associated with menstruation. Taking zolmitriptan during the aura did not prevent migraine headache, so the drug should be taken after the onset of a painful attack.

Indications:

Relief of migraine attacks with or without aura.

Method of administration and dosage:

Stick the film on the surface of the tongue with dry hands.

The recommended dose of the drug for relieving a migraine attack is 2.5 mg (1 film). It is recommended to take the drug as early as possible after the onset of the headache, but the drug is effective when taken later after the onset of the attack.

If migraine symptoms recur within 24 hours, you can take a second dose of the drug. Do not take a second dose earlier than 2 hours after taking the first dose. If there is no clinical response after taking the first dose, it is unlikely that the drug will be beneficial again during the same attack.

If the patient has not achieved a therapeutic effect after taking a dose of 2.5 mg, Zolmsolan at a dose of 5 mg can be used to relieve subsequent migraine attacks.

Do not take more than 2 doses of the drug per day. The total dose of zolmitriptan taken during the day should not exceed 10 mg.

Zolmsolan is not indicated for the prevention of migraines.

Contraindications:

– hypersensitivity to any components of the drug;

-hemiplegic, basilar and ophthalmoplegic migraine;

-uncontrolled arterial hypertension;

-cardiac ischemia;

– Coronary vasospasm / Prinzmetal angina;

– Wolff-Parkinson-White syndrome or arrhythmias associated with other additional pathways of impulse conduction;

– diseases of the peripheral arteries;

– a history of cerebral circulation (including stroke or transient ischemic attack);

– severe renal failure (CC less than 15 ml / min);

– joint use with other agonists of serotonin 5HT1B / 1D-receptors (for example, sumatriptan, naratriptan), ergotamine or its derivatives (including metizergide), as well as within 24 hours after their cancellation;

– joint use with MAO-A inhibitors and within 14 days after their cancellation;

-lactose intolerance, lactase deficiency or glucose-galactose malabsorption;

-period of pregnancy (safety of use has not been studied);

-Children up to 18 years old;

elderly age over 65 years (efficacy and safety of use have not been studied).

Precautionary measures:

The drug can be used only in cases of clearly diagnosed migraine. Before prescribing zolmitriptan, as well as other agents for the relief of migraine, it is necessary to exclude other possible serious neurological diseases in patients with previously undiagnosed migraine, as well as in patients with an established diagnosis of migraine in the presence of atypical symptoms. Zolmitriptan is not indicated for the treatment of hemiplegic, basilar and ophthalmoplegic migraines. In patients taking agonists of serotonin 5HT1B / 1D receptors, cerebrovascular accidents were observed, incl. stroke. Migraine patients may be at risk of developing certain disorders of the cerebral circulation.

Side effects:

From the nervous system: often – disturbances in sensitivity, dizziness, hyperesthesia, paresthesia, drowsiness, a feeling of warmth or cold, vertigo.

From the side of the cardiovascular system: often – a feeling of palpitations.

From the digestive system: often – abdominal pain; nausea, vomiting, dry mouth.

From the musculoskeletal system: often – muscle weakness, myalgia.

Storage method:

Store at a temperature not higher than

30 degrees.

Package:

The cardboard box contains 6 films dissolving in the mouth, paper instructions.